ATLANTA, March 18, 2021 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announced today that President and CEO Rick Eiswirth will participate in the Benzinga Biotech Small Cap Conference to be held March 24-25, 2021.
Mr. Eiswirth will present on March 25 at 12:00 pm ET.
Investors can view Mr. Eiswirth’s general corporate presentation once they register for the conference here and can also request a 1×1 meeting with Mr. Eiswirth.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com |
For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP)…
WALLINGFORD, Conn., June 18, 2024 /PRNewswire/ -- InsiteOne, a leading provider of cloud-based Vendor Neutral Archive…
BETHLEHEM, Pa., June 18, 2024 /PRNewswire/ -- Young Women's Christian Association of Bethlehem PA ("YWCA…
Fidelity Management & Research Company Leads Financing; Nexus Neurotech Ventures and Ally Bridge Group Co-Lead…
Combined entity delivers the ICyte® revenue optimization platform powered by first-party data, AI-enabled data exploration,…
CHICAGO, June 18, 2024 /PRNewswire/ -- WellBe Senior Medical and its affiliated medical groups announce…